Thursday, May 02, 2019 10:58:00 PM
Going back historically, what got PSS to move big were the pre-clinical studies from 3$ to 15$ (.10 to .50 back then).
Given that history is generally the best predictor, I suspect that is what the market looking for now, and that excellent surgeon feedback on the improved SPORT with the animal and cadaver studies taking place this quarter will make it move.
In other words, did the system overcome the limitations of the previous prototype (esp. issues with insertion, camera range of motion, and lens cleaning), and how much better is the new system in other respects we don't even yet know about?
Personally, I like this scenario far better, than hoping for something fluffy like rebranding to move the needle. It goes straight to the core of the issue. Does the machine work as intended and will it sell well once approved?
This is wall street after all...money talks...
I don't expect us to go to 15 like the last time, because excellent reviews will be more baked-in than the last time, but I think it will count for something...
I do also still expect a belated reaction to the design freeze over time. Shorts have pounded on this stock, and there's still a lot resistance. But there's no reason we won't climb back to the recent highs of 4.50 once we're past that.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM